LGK974 for Esophageal Squamous Cell Carcinoma

Phase-Based Progress Estimates
Esophageal Squamous Cell Carcinoma+7 MoreLGK974 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug called LGK974 to see if it is safe and effective in treating adults with cancer that has progressed despite standard therapy or for which no effective standard therapy exists.

Eligible Conditions
  • Esophageal Squamous Cell Carcinoma
  • BRAF Mutant Colorectal Cancer
  • Squamous Cell Carcinoma of the Lung
  • Squamous Cell Head and Neck Cancers
  • Melanoma
  • Pancreatic Cancer
  • Breast Cancer
  • Cervical Squamous Cell Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: 61 months

34 months
Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated
61 months
Absorportion and plasma concentrations of PDR001
Absorption and plasma concentrations of LGK974
Biomarkers related to immunomodulation
Biomarkers related to the Wnt pathway
Overall response rate of tumor
PD related to the Wnt pathway
Type and category of study drug related adverse events (AE)

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

1 of 2
LGK974 in combination with PDR001
1 of 2

Experimental Treatment

185 Total Participants · 2 Treatment Groups

Primary Treatment: LGK974 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: LGK974 · Intervention Types: Drug
LGK974 in combination with PDR001Experimental Group · 2 Interventions: LGK974, PDR001 · Intervention Types: Drug, Biological
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 61 months

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,718 Previous Clinical Trials
3,524,834 Total Patients Enrolled
4 Trials studying Esophageal Squamous Cell Carcinoma
412 Patients Enrolled for Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients with BRAF V600-mutant melanoma must have also received and been failed by prior systemic therapy with BRAF V600 inhibitor, with or without a MEK inhibitor.
You have cutaneous melanoma with acquired resistance to prior anti-PD-1 therapy, defined as progressive disease following response (PR or CR) or following stable disease for > 4 months.